Predictive Factors for Re-Bleeding and Mortality Following Histoacryl Glue Injection in Gastric Variceal Hemorrhage

Gastric variceal hemorrhage is a severe complication of portal hypertension with high morbidity and mortality. Despite advances in endoscopic therapy, re-bleeding remains a major concern. This study investigates predictive factors for re-bleeding and mortality in patients treated with Histoacryl® glue injection for acute gastric variceal hemorrhage, based on a retrospective analysis of 90 cases from Siriraj Hospital.

The cohort included 90 patients (74.4% male) with a mean age of 55.9 ± 13.9 years. Most presented with hematemesis (71.1%), and underlying liver disease was due to cirrhosis from alcoholism (34.4%), hepatitis B (28.9%), or hepatitis C (14.4%). The Child-Pugh classification revealed 20.0% class A, 46.7% class B, and 32.2% class C. The median MELD score was 10 (range: 6–28).

All patients underwent endoscopic Histoacryl® injection using a standardized technique: a 0.5 mL Histoacryl® and 0.8 mL lipiodol mixture injected via a primed catheter. Initial hemostasis was achieved in 97.8% of cases. Early re-bleeding occurred in 10.0%, while late re-bleeding developed in 21.1%. Univariate analysis identified ascites as significantly associated with both early (OR = 10.90, P = 0.01) and late re-bleeding (OR = 4.25, P = 0.01). Multivariate analysis confirmed that ascites remained an independent predictor of both early (OR = 10.67, P = 0.03) and late (OR = 4.15, P = 0.01) re-bleeding.

Mortality was 21.1%, primarily due to infection (52.4-Iodophenylboronic acid site 6% of deaths), advanced cirrhosis, or hepatocellular carcinoma. Univariate analysis linked mortality to ascites (OR = 3.09, P = 0.04), elevated total bilirubin (OR = 16.7, P < 0.01), high-volume packed red blood cell transfusion (P < 0.01), fresh frozen plasma use (P < 0.01), emergency endoscopy (OR = 0.17, P = 0.02), large glue volume (P < 0.01), and re-bleeding episodes. Multivariate analysis narrowed the predictors to three: elevated total bilirubin (OR = 16.71, P < 0.01), large-volume fresh frozen plasma transfusion (OR = 1.001, P = 0.03), and late re-bleeding (OR = 10.99, P = 0.02). ROC analysis identified a total bilirubin cutoff of >4.5 mg/dL as highly predictive of mortality (AUC = 0.926). Patients with bilirubin above this threshold had a significantly higher risk of death (OR = 7.Benzylhydrazine supplier 25, P < 0.PMID:34551150 01).

Notably, no significant correlation was found between re-bleeding or mortality and varix type (GOV1, GOV2, IGV1, IGV2), varix size, number of injections, or the amount of glue used. Endoscopic signs of recent bleeding also failed to predict outcomes.

In conclusion, ascites and elevated bilirubin are strong independent predictors of re-bleeding and mortality following Histoacryl® injection. These findings highlight the critical role of pre-existing liver dysfunction in determining clinical outcomes. Patients with decompensated liver disease, especially those with ascites or jaundice, require intensified monitoring and potential early consideration of alternative therapies such as TIPS or B-RTO. Early identification of high-risk patients may improve survival through timely intervention and optimized post-procedural management.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com